miR-186 Regulates Septic Hyperinflammation and Predicts Sepsis

Area of Science:

• Molecular Biology
• Immunology
• Critical Care Medicine

Background:

• Sepsis, a life-threatening infection-induced immune response, is challenging to differentiate from infection due to similar clinical signs.
• The specific role of microRNA-186 (miR-186) in sepsis pathogenesis and its diagnostic utility remain largely unexplored.
• miR-186 is known to regulate cell proliferation, apoptosis, and potentially immune-related genes.

Purpose of the Study:

• To investigate the expression levels of miR-186 in patients with sepsis versus infection.
• To evaluate the diagnostic performance of miR-186 as a sepsis biomarker.
• To explore the functional role of miR-186 in sepsis-related immune responses.

Main Methods:

• Retrospective enrollment of 21 infected and 20 sepsis patients.
• Quantification of miR-186 in blood cells via real-time PCR.
• Assessment of cytokine concentrations and lymphocyte subsets using flow cytometry.
• In vitro and in vivo experiments involving miR-186 inhibition in endothelial cells and mice.

Main Results:

• miR-186 expression was significantly higher in sepsis patients compared to infected patients.
• miR-186 demonstrated superior diagnostic performance for sepsis over procalcitonin and lactate.
• Lipopolysaccharide (LPS) stimulation increased miR-186 expression in a dose-dependent manner.
• Inhibition of miR-186 reduced pro-inflammatory cytokine (IL-1β, IL-6, IL-8) expression in vitro and decreased IL-1β and natural killer cell ratios in vivo.

Conclusions:

• miR-186 is significantly upregulated in sepsis and contributes to immune dysregulation.
• miR-186 shows promise as a novel diagnostic biomarker for early sepsis detection.
• Targeting miR-186 may offer a therapeutic strategy for managing sepsis-induced inflammation.